EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration

Paula Teichner, Nadine Chamay, Emilie Elliot, Miguel Pascual-Bernáldez, Deanna Merrill, Cindy Garris, Ronald D'Amico, Cecy Felizarta, Emma Torres, Rodica Van Solingen-Ristea, Bryan Baugh, Parul Patel und 8 weitere

Open Forum Infectious Diseases · 03.06.2024 · 11 (6)

DOI: 10.1093/ofid/ofae282 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 25.05.2024. Verfasst von Paula Teichner und 19 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare, Janssen Research & Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cabotegravir (CAB) + rilpivirine (RPV) dosed monthly or every 2 months is a complete long-acting (LA) regimen for the maintenance of human immunodeficiency virus type 1 virologic suppression. Across the phase 3/3b trials, the most frequently reported adverse events were injection site reactions (ISRs).

Methods

We present pooled ISR characteristics and outcomes for participants receiving CAB + RPV LA through week 96 of the FLAIR and ATLAS-2M studies, and survey results from healthcare providers (HCPs) giving injections (eg, injectors) in the ATLAS, FLAIR, and ATLAS-2M studies to determine optimal injection techniques. Surveys were anonymous, self-administered online questionnaires that queried provider demographics, injection experience, and techniques to minimize pre-/postinjection discomfort. Data were summarized using descriptive statistics.

Results

Overall, 8453 ISRs were reported by 801 participants receiving ≥1 injection of CAB LA/RPV LA. Most ISRs were mild to moderate in severity (grade 1–2, 99%), with a median duration of 3 days (interquartile range, 2–4 days), and rarely led to withdrawal (2%). Surveys were completed by 181 HCPs across 113 sites. Pushing the intramuscular injection at slow speed (66%), bringing the medication to room temperature (58%), and relaxing the gluteus muscle before injecting (53%) were ranked as effective preinjection/injection procedure practices for minimizing pain. Most injectors (60%) indicated that a prone position provided optimal patient comfort, and 41% had no preference on injection medication order.

Conclusions

Taken together, the data demonstrate favorable tolerability with CAB + RPV LA injections over the long term and simple techniques routinely used by injectors to help optimize the administration of CAB + RPV LA injections.

Schlagwörter

Stichwörter der Autor:innen

HIV-1cabotegravirinjection site reactionlong-acting therapyrilpivirine

Autor:innen und Institutionen

  • ViiV Healthcare, Durham, North Carolina, USA.
  • ViiV Healthcare, Brentford, United Kingdom.
  • ViiV Healthcare, Madrid, Spain.
  • Private practice of Franco Felizarta, MD, Bakersfield, California, USA.
  • Service de maladies infectieuses et tropicales, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Janssen Research and Development, Beerse, Belgium.

Förderung

  • ViiV Healthcare
  • Janssen Research & Development

Zitieren

APA

Teichner, P., Chamay, N., Elliot, E., Pascual-Bernáldez, M., Merrill, D., Garris, C., D'Amico, R., Felizarta, C., Torres, E., Van Solingen-Ristea, R., Baugh, B., Patel, P., Vannappagari, V., Dakhia, S., Polli, J. W., Garside, L., Grove, R., Thiagarajah, S., Birmingham, E., & van Wyk, J. (2024). Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration. Open Forum Infectious Diseases, 11(6). https://doi.org/10.1093/ofid/ofae282

Vancouver

Teichner P, Chamay N, Elliot E, Pascual-Bernáldez M, Merrill D, Garris C, et al. Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration. Open Forum Infectious Diseases. 2024;11(6). doi:10.1093/ofid/ofae282

BibTeX
@article{Teichner2024,
  author = {Teichner, Paula and Chamay, Nadine and Elliot, Emilie and Pascual-Bernáldez, Miguel and Merrill, Deanna and Garris, Cindy and D'Amico, Ronald and Felizarta, Cecy and Torres, Emma and Van Solingen-Ristea, Rodica and Baugh, Bryan and Patel, Parul and Vannappagari, Vani and Dakhia, Samia and Polli, Joseph W and Garside, Louise and Grove, Richard and Thiagarajah, Shanker and Birmingham, Eileen and van Wyk, Jean},
  title = {Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration},
  journal = {Open Forum Infectious Diseases},
  year = {2024},
  volume = {11},
  number = {6},
  doi = {10.1093/ofid/ofae282}
}
Kostenlos starten →